ASVRX | TMVAX | ASVRX / TMVAX | |
Total Expense Ratio | 1.59 | 1.34 | 119% |
Annual Report Gross Expense Ratio | 1.59 | 1.64 | 97% |
Fund Existence | 15 years | 21 years | - |
Gain YTD | -2.555 | 2.706 | -94% |
Front Load | N/A | 6% | - |
Min. Initial Investment | 2500 | 1000 | 250% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 4.8B | 110M | 4,366% |
Annual Yield % from dividends | 0.42 | 1.60 | 26% |
Returns for 1 year | -1.10 | 9.48 | -12% |
Returns for 3 years | 11.16 | 2.93 | 381% |
Returns for 5 years | 67.04 | 43.88 | 153% |
Returns for 10 years | 10.24 | 3.40 | 302% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BGLTX | 37.93 | 0.49 | +1.30% |
Baillie Gifford Long Term Global Gr 2 | |||
GSBEX | 15.91 | 0.17 | +1.08% |
Goldman Sachs Small Cap Growth R6 | |||
PEAPX | 30.56 | 0.19 | +0.63% |
Principal Glb Emerging Markets R3 | |||
HHCAX | 16.04 | 0.03 | +0.19% |
NexPoint Event Driven A | |||
VEUPX | 185.11 | -0.17 | -0.09% |
Vanguard European Stock Instl Plus |